Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Seragon

This page shows the latest Seragon news and features for those working in and with pharma, biotech and healthcare.

Roche boosts respiratory presence with InterMune purchase

Roche boosts respiratory presence with InterMune purchase

These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing

Latest news

  • Chugai soars on Roche buyout rumours Chugai soars on Roche buyout rumours

    Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing

  • Roche makes $1.7bn oncology acquisition Roche makes $1.7bn oncology acquisition

    According to Roche, this pipeline of products complements the breast cancer programmes of its biotech division Genentech, which will assume control of Seragon. ... Seragon was only created last year when it was spun out from cancer drug specialist Aragon

  • J&J completes Aragon deal as Seragon is born J&J completes Aragon deal as Seragon is born

    Seragon spun out. The closure of the deal also sees the creation of a new pharma company - Seragon Pharmaceuticals - that will take over development of other Aragon development programmes, including metastatic ... Seragon is focused on developing new

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    Roche – in and out and round about. Following on from last month's $1.73bn acquisition of Seragon Pharmaceuticals, Roche seems to be in mood-swing mode backing out of one

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    2, 095. Seragon Pharmaceuticals/ Genentech. Company acquisition . Selective Estrogen Receptor Degrader (SERD) platform for hormone dependent breast cancer, inc ARN-810 (p1).

  • Pharma deals during July 2014 Pharma deals during July 2014

    Further sales-related payments may also be payable by AZ. At the very start of the month, Genentech announced its intention to buy Seragon Pharmaceuticals for $725m cash upfront with ... Seragon's focus is in hormone dependent cancers and specifically

  • Pharma deals during June 2013 Pharma deals during June 2013

    Interestingly, J&J is not getting the entire company pipeline however, as Aragon is spinning out the selective oestrogen receptor degrader platform into a new company, Seragon Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links